Processing your request

please wait...

Case Page


Case Status:    ONGOING  
—On or around 06/06/2024 (Date of last review)
Current/Last Presiding Judge:  
Hon. John R. Padova

Filing Date: June 05, 2024

According to the Complaint, Marinus Pharmaceuticals, Inc. describes itself as a “commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone).” Pertinent to this action is the Randomized Therapy in Status Epilepticus trial (RAISE), which the Company has described as a “pivotal Phase 3 trial in refractory status epilepticus (RSE) patients.”

The Complaint alleges that Defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) Defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Protected Content

Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.